Bayer-starts-Phase-III-clinical-development-program-OASIS-with-Elinzanetant

Elinzanetant is an innovative non-hormonal development compound investigated for the treatment of vasomotor symptoms during menopause
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news